USC Voice Center, Caruso Department of Otolaryngology, Head and Neck Surgery, Keck School of Medicine, Los Angeles, California, U.S.A.
Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, McMaster University, Ontario, Canada.
Laryngoscope. 2024 Dec;134(12):5021-5027. doi: 10.1002/lary.31683. Epub 2024 Aug 8.
Vocal fold scar and sulcus pose significant treatment challenges with no current optimal treatment. Platelet-rich plasma (PRP), an autologous concentration of growth factors, holds promise for regenerating the superficial lamina propria. This study aims to evaluate the potential benefits of serial PRP injections on mucosal wave restoration and vocal function.
In a prospective clinical trial across two institutions, patients with vocal fold scar underwent four serial PRP injections, one month apart. Blinded independent laryngologists and expert listeners used pretreatment and one-month post-fourth injection videostroboscopy and CAPE-V assessments to evaluate mucosal wave and voice quality changes, respectively. Additionally, patient reported outcome measures (PROMs) were evaluated.
In the study, 15 patients received 55 PRP injections without adverse effects. Eight patients (53.3%) had mild, three patients (20%) had moderate, and four patients (26.7%) had severe scar. There was an average reduction of 8.7 points in post-treatment VHI-10 scores (p = 0.007). The raters observed an improvement in post-treatment voice in 73.4% of cases, and CAPE-V scores showed a reduction of 18.8 points on average (p = 0.036). The videostroboscopic VALI ratings showed an improvement in mucosal wave rating from 2.0 to 4.0. On average, the raters perceived the post-PRP exams to be better in 56.7% of cases.
PRP has been validated as a safe autologous option for treatment of vocal fold scar. While results for mucosal wave and voice quality varied, there was a consistent improvement in PROMs.
3: Prospective cohort study, with blinded analysis Laryngoscope, 134:5021-5027, 2024.
声带瘢痕和沟是治疗的重大挑战,目前尚无最佳治疗方法。富含血小板的血浆(PRP)是一种自体生长因子浓缩物,有望再生浅层固有层。本研究旨在评估连续 PRP 注射对黏膜波恢复和嗓音功能的潜在益处。
在两个机构的前瞻性临床试验中,声带瘢痕患者接受了 4 次连续 PRP 注射,间隔 1 个月。盲法独立喉镜医师和专家听众使用预处理和第四次注射后 1 个月的视频频闪喉镜和 CAPE-V 评估分别评估黏膜波和语音质量变化。此外,还评估了患者报告的结局测量(PROMs)。
在这项研究中,15 名患者接受了 55 次 PRP 注射,没有不良反应。8 名患者(53.3%)有轻度瘢痕,3 名患者(20%)有中度瘢痕,4 名患者(26.7%)有重度瘢痕。治疗后 VHI-10 评分平均降低 8.7 分(p=0.007)。评估者观察到 73.4%的病例治疗后嗓音有所改善,CAPE-V 评分平均降低 18.8 分(p=0.036)。频闪喉镜 VALI 评分显示黏膜波评分从 2.0 提高到 4.0。评估者平均认为 56.7%的病例在接受 PRP 检查后更好。
PRP 已被验证为治疗声带瘢痕的安全自体选择。虽然黏膜波和语音质量的结果不同,但 PROMs 有一致的改善。
3:前瞻性队列研究,具有盲法分析喉镜,134:5021-5027,2024。